Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients

Kamran MA Aziz Aseer Diabetes Center, Aseer Central Hospital, Ministry of Health, Abha, Saudi Arabia Abstract: Diabetes management during Ramadan fasting is challenging to the physician in terms of minimizing the risk of hypoglycemia. As compared to oral hypoglycemic agents (OHAs) and sulfonylureas...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Aziz KMA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/ce42027a5dff45f9a689e17a89fda098
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ce42027a5dff45f9a689e17a89fda098
record_format	dspace
spelling	oai:doaj.org-article:ce42027a5dff45f9a689e17a89fda0982021-12-02T00:32:47ZFasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients1178-7007https://doaj.org/article/ce42027a5dff45f9a689e17a89fda0982015-04-01T00:00:00Zhttp://www.dovepress.com/fasting-during-ramadan-efficacy-safety-and-patient-acceptability-of-vi-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Kamran MA Aziz Aseer Diabetes Center, Aseer Central Hospital, Ministry of Health, Abha, Saudi Arabia Abstract: Diabetes management during Ramadan fasting is challenging to the physician in terms of minimizing the risk of hypoglycemia. As compared to oral hypoglycemic agents (OHAs) and sulfonylureas (SUs), which carry a higher and significant risk of hypoglycemia, newer antidiabetic agents such as dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated lower risk of hypoglycemia during Ramadan fasting, with better patient compliance. In addition to diabetes education and pre-Ramadan assessments, the physician should also consider use of DPP-4 inhibitors (such as vildagliptin) during Ramadan fasting to minimize the risk of hypoglycemia in type 2 diabetic subjects. Severe episodes of hypoglycemia have been demonstrated in recent research and clinical trials with OHAs/SUs. Conversely, these research observations have also demonstrated comparative safety and efficacy with lower risk of hypoglycemia associated with vildagliptin. Current research review has collected evidence-based clinical trials and observations for the drug vildagliptin to minimize the risk of hypoglycemia during Ramadan fasting, while at the same time focusing the role of diabetes self-management education (DSME), pre-Ramadan assessments, and patient care. Keywords: hypoglycemia, DPP4-inhibitors, oral hypoglycemic agents, Ramadan fasting, type 2 diabetes, vildagliptinAziz KMADove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 207-211 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Aziz KMA Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
description	Kamran MA Aziz Aseer Diabetes Center, Aseer Central Hospital, Ministry of Health, Abha, Saudi Arabia Abstract: Diabetes management during Ramadan fasting is challenging to the physician in terms of minimizing the risk of hypoglycemia. As compared to oral hypoglycemic agents (OHAs) and sulfonylureas (SUs), which carry a higher and significant risk of hypoglycemia, newer antidiabetic agents such as dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated lower risk of hypoglycemia during Ramadan fasting, with better patient compliance. In addition to diabetes education and pre-Ramadan assessments, the physician should also consider use of DPP-4 inhibitors (such as vildagliptin) during Ramadan fasting to minimize the risk of hypoglycemia in type 2 diabetic subjects. Severe episodes of hypoglycemia have been demonstrated in recent research and clinical trials with OHAs/SUs. Conversely, these research observations have also demonstrated comparative safety and efficacy with lower risk of hypoglycemia associated with vildagliptin. Current research review has collected evidence-based clinical trials and observations for the drug vildagliptin to minimize the risk of hypoglycemia during Ramadan fasting, while at the same time focusing the role of diabetes self-management education (DSME), pre-Ramadan assessments, and patient care. Keywords: hypoglycemia, DPP4-inhibitors, oral hypoglycemic agents, Ramadan fasting, type 2 diabetes, vildagliptin
format	article
author	Aziz KMA
author_facet	Aziz KMA
author_sort	Aziz KMA
title	Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
title_short	Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
title_full	Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
title_fullStr	Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
title_full_unstemmed	Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
title_sort	fasting during ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/ce42027a5dff45f9a689e17a89fda098
work_keys_str_mv	AT azizkma fastingduringramadanefficacysafetyandpatientacceptabilityofvildagliptinindiabeticpatients
_version_	1718403707148697600

Fasting during Ramadan: efficacy, safety, and patient acceptability of vildagliptin in diabetic patients

Ejemplares similares